Cocrystal Pharma, Inc. COCP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Cocrystal Pharma, Inc. (COCP) is a healthcare company listed in the US with a market value of about $19M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -72%.
About Cocrystal Pharma
Cocrystal Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 39% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $2M | $7M | — | — | — |
| Net income | -$9M | -$18M | -$18M | -$39M | -$14M | -$10M | -$48M | -$49M | -$613000 | -$75M |
| Free cash flow | -$8M | -$16M | -$15M | -$22M | -$13M | -$10M | -$2M | -$8M | -$7M | -$15M |
| EPS (diluted) | $-0.78 | $-1.72 | $-1.87 | $-4.77 | $-0.16 | $-0.17 | $-0.00 | $-0.00 | $-0.03 | $-3.30 |
| Net margin | — | — | — | — | — | -479.0% | -733.8% | — | — | — |
| ROIC | -90.9% | -124.7% | -51.9% | -76.9% | -14.4% | -14.3% | -144.8% | -73.7% | -6.1% | -74.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Cocrystal Pharma pay a dividend?
Not currently.
Is Cocrystal Pharma a good stock to buy?
We do not give buy or sell advice. Cocrystal Pharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.